Journal
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
Volume 66, Issue 4, Pages 419-426Publisher
SPRINGER HEIDELBERG
DOI: 10.1007/s00228-009-0771-z
Keywords
C1-inhibitor deficiency; Treatment; Ultrasound; Safety; Side effect; Danazol; Liver function
Categories
Ask authors/readers for more resources
Danazol is a drug most widely used for the prophylaxis of hereditary angioedema resulting from the deficiency of the C1-inhibitor. Potential hepatotoxic or liver tumor-inducing side effects of long-term danazol prophylaxis have been investigated during the follow-up of hereditary angioedema patients. Characteristic parameters of liver function (including bilirubin, GOT, GPT, gamma GT, total protein, ALP, LDH), as well as findings of viral serology screens and abdominal ultrasonography-determined during years 0 and 5 of follow-up of patient groups taking/not taking danazol-have been reviewed and analyzed comparatively. From a population of 126 hereditary angioedema patients, 46 subjects taking danazol and another 46 not taking danazol fulfilled the inclusion criteria. Longitudinal follow-up did not reveal any clinically relevant difference between the liver function parameters determined in years 0 and 5 in the two groups. Abdominal ultrasound did not detect neoplastic or other potentially treatment-related alterations of the liver parenchyma. There were no discontinuations of treatment during the study. Our results clearly suggest that, administered at the lowest effective dose, danazol does not induce liver injury in hereditary angioedema patients.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available